Stoke Therapeutics (STOK) Operating Margin (2022 - 2026)
Stoke Therapeutics (STOK) recorded quarterly Operating Margin of 857.57% in Q1 2026, up 80.43% quarter-over-quarter from 4382.24% in Q4 2025, and down 92772.0% on a YoY basis from N/an in Q1 2025.
Stoke Therapeutics (STOK) Operating Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' Operating Margin history runs 5 years deep, the most recent figure standing at 857.57% for Q1 2026.
- In Q1 2026, Operating Margin fell 92772.0% year-over-year to 857.57%; the TTM figure through Mar 2026 stood at 577.46% (down 59749.0% YoY), while the FY2025 annual figure was 11.16%, up 26615.0% from the prior year.
- Operating Margin was 857.57% for Q1 2026 at Stoke Therapeutics, up from 4382.24% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 70.15% in Q1 2025 to a low of 4382.24% in Q4 2025.
- Historically, Operating Margin has averaged 870.53% across 5 years, with a median of 781.12% in 2022.
- The sharpest annual moves came in 2024 and 2025: Operating Margin soared 99551 bps in 2024, then sank 432187 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 831.58% in 2022, then declined by 27 bps to 1055.89% in 2023, then surged by 94 bps to 60.37% in 2024, then sank by 7158 bps to 4382.24% in 2025, then jumped by 80 bps to 857.57% in 2026.
- The last three Operating Margin figures came in at 857.57% (Q1 2026), 4382.24% (Q4 2025), and 405.3% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.95 Bn | - | -857.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -857.57% |
| Dec 31, 2025 | -4,382.24% |
| Sep 30, 2025 | -405.30% |
| Jun 30, 2025 | -197.58% |
| Mar 31, 2025 | 70.15% |
| Dec 31, 2024 | -60.37% |
| Sep 30, 2024 | -613.06% |
| Jun 30, 2024 | -607.37% |
| Mar 31, 2024 | -672.96% |
| Dec 31, 2023 | -1,055.89% |
| Sep 30, 2023 | -823.28% |
| Jun 30, 2023 | -1,340.67% |
| Mar 31, 2023 | -479.23% |
| Dec 31, 2022 | -831.58% |
| Sep 30, 2022 | -934.53% |
| Jun 30, 2022 | -781.12% |
| Mar 31, 2022 | -826.50% |